Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/29/2024 | $8.00 → $2.00 | Outperform → Neutral | Wedbush |
| 9/22/2023 | $11.00 | Outperform | Wedbush |
| 5/4/2023 | $18.00 | Buy | H.C. Wainwright |
| 12/23/2021 | $25.00 | Buy | HC Wainwright & Co. |
| 8/13/2021 | $30.00 → $27.00 | Outperform | Credit Suisse |
4 - Ikena Oncology, Inc. (0001835579) (Issuer)
4 - Ikena Oncology, Inc. (0001835579) (Issuer)
4 - Ikena Oncology, Inc. (0001835579) (Issuer)
The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflamma
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.
Combined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") today announced the results of the annual meeting of its stockholders held on July 15, 2025. At the annual meeting, Ikena's stockholders voted in favor of all proposals, including a proposal approving the previously announced merger with Inmagene Biopharmaceuticals ("Inmagene"). The merger proposal allows for the issuance of shares of Ikena's common stock both to the shareholders of Inmagene and to the investors of the financing concurrent to the merger. Following th
Wedbush downgraded Ikena Oncology from Outperform to Neutral and set a new price target of $2.00 from $8.00 previously
Wedbush initiated coverage of Ikena Oncology with a rating of Outperform and set a new price target of $11.00
H.C. Wainwright resumed coverage of Ikena Oncology with a rating of Buy and set a new price target of $18.00
8-K - Ikena Oncology, Inc. (0001835579) (Filer)
10-Q - Ikena Oncology, Inc. (0001835579) (Filer)
8-K - Ikena Oncology, Inc. (0001835579) (Filer)
Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena"))), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, Inc. (Pionyr), a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena's acquisition of Pionyr in an all-stock transaction. Ikena acquired all of Pionyr's assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a com
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.
Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum
BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena, " "Company"))) today announced financial results for the second quarter ended June 30, 2024, and provided an update regarding its ongoing activities. Pipeline Updates Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared their safety evaluation period Promising early pharmacokinetics (PK) and pharmacodynamics (PD) activity has been observed, with dose dependent exposure and target modulation measured in the blood In May 2024, the Company announced the discontinuation of the IK-930 clinical program Corporate Updates In
SC 13G - Ikena Oncology, Inc. (0001835579) (Subject)
SC 13G/A - Ikena Oncology, Inc. (0001835579) (Subject)
SC 13G/A - Ikena Oncology, Inc. (0001835579) (Subject)